Interventions with paclitaxel drug-coated balloons
PCR statement on clinical outcomes after interventions with paclitaxel drug-coated balloons
Paris, France, 21 May 2019. This PCR statement on paclitaxel drug-coated balloons (DCB) use in peripheral interventions addresses the controversy raised by the meta-analysis of K. Katsanos, MD, PhD (Patras University Hospital, Rion, Greece) and colleagues, published in late 2018. The Katsanos meta-analysis prompted widespread concern in the interventional community by suggesting that treatment with paclitaxel-eluting stents or DCBs for femoropopliteal disease is associated with increased
death beyond 1 year out to 5 years compared with uncoated balloon therapy.
The statement outlines that, as for any meta-analysis, the Katsanos analysis is subject to major inherent methodological limitations that prevent reliable interpretation of the primary findings. These include the use of study-level (rather than patient-level) data, limited longterm
data and high dropout rates (>80% loss of patient data at 4-5 years), unknown repeated exposure to paclitaxel during re-interventions, lack of adjudication of causes of death, and subsequent corrections to primary source data (announced in February 2019).
The Statement acknowledges that, while the results of the meta-analysis itself were far from conclusive, further evaluation is warranted given the widespread use of paclitaxel in peripheral interventions and the implications of the reported hazard. The publication did
serve as a wakeup call and swift action on the part of the interventional community, including industry and the FDA, to convene collaborative discussions, new analyses and presentations of patient level pooled data. A planned industry-wide pooled analysis is anticipated to be
presented at an upcoming FDA panel meeting in mid-June, with rapid dissemination of preliminary findings and planned next steps to the broader physician community.
The statement emphasises that additional evidence from individual sponsor-driven patientlevel analyses of clinical trial data, as well as large-scale claims data, have failed to replicate the results of the meta-analysis with respect to an association of paclitaxel exposure with
long-term mortality. Furthermore, no safety signal has ever been shown in coronary DCB applications in the long-term.
PCR acknowledges the vital need for a carefully conducted and adjudicated industry-wide patient level pooled analysis to compare long-term safety outcomes. This analysis is planned to be presented at the upcoming FDA panel on June 19th and 20th. Finally, PCR strongly
supports resuming, under careful safety oversight, two large prospective randomised trials (BASIL 3 and SWEDPAD) that were suspended shortly after the Katsanos publication. These trials would provide the vital evidence necessary to evaluate the safety of DCB to better inform clinicians in everyday practice.
Pending the availability of more conclusive data, there is currently no strong evidence to justify changing clinical practice and clinicians should continue to use best judgment in the use of paclitaxel-based DCBs.
NOTES TO EDITORS
- A PCR statement on clinical outcomes after interventions with paclitaxel drug-coated
balloons presented by Alexandra Lansky
- Palais des Congres Porte Maillot – Paris, France
- Tuesday 21 May 2019 – 15:30- Theatre Bordeaux
About EuroPCR 2019
The World-Leading Course in interventional cardiovascular medicine and the official annual
meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) will take place from 21 to 24 May 2019 at the Palais des Congres – Paris, France. The detailed Course Programme is available on: https:/
The mission of PCR is to serve the needs of each individual patient by helping the cardiovascular community to share knowledge, experience and practice. PCR offers a large range of many other educational meetings and resources for the continuing education of the interventional cardiovascular community. These include major annual Courses across the globe, e-Learning with high-profile PCR Webinars, Courses specifically dedicated to valvular heart disease, tailormade
PCR Seminars on specific topics, online resources and medical publications such as EuroIntervention, the official journal of the EAPCI.
Gateways to all PCR activities are available on http://www.
For further information, please contact Celia Vila: email@example.com
HELP FOR JOURNALISTS TO COVER EUROPCR 2019
Register and attend EuroPCR 2019 as a journalist
Open to accredited journalists, free of charge. Journalists must hold a valid press card and/or provide a letter of assignment from a recognised publication. To register as press go to https:/
EuroPCR press releases can be found at
For the press briefing schedule check
For any press-related enquiries, please contact
EuroPCR Press Coordinator, Isabelle Uzielli: firstname.lastname@example.org